Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined - 25 Superstar Couples That Motivate Relationship Objectives
- 3How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 4Best Pizza Beating: What's Your #1?
- 5I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Which Breakfast Enraptures Your Taste Buds? Vote
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Top 15 Web-based Entertainment Stages for Individual Marking
- Blood pressure drug recalled for possible cross-contamination
- Improving as a Cook: Culinary Experiences in the Kitchen
- Polar bears are rewiring their own genetics to survive a warming climate
- New hybrid mpox strain discovered in UK after US reports local spread
- Figure out How to Reveal Stowed away Open Record Rewards
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
